NUS1 Gene — NUS1 Homolog (Coenzyme Q Biosynthesis Factor)
Overview
NUS1 (NUS1 Homolog), also known as COQ8B or NgBR, encodes a critical component of the coenzyme Q (CoQ) biosynthesis pathway. Coenzyme Q (ubiquinone) is an essential electron carrier in the mitochondrial respiratory chain and a potent antioxidant that plays fundamental roles in cellular energy production and protection against oxidative stress.[@martin2019] NUS1 forms a heterodimer with COQ8A to form the CoQ biosynthesis complex, which catalyzes essential steps in ubiquinone synthesis throughout the body, with particularly critical functions in highly energy-dependent tissues such as the brain and heart.[@heregami2004]
The discovery that NUS1 mutations cause primary coenzyme Q10 deficiency established this gene as a fundamental component of mitochondrial function and highlighted its importance in neurodegenerative disease pathogenesis.[@stefely2016] Beyond its role in CoQ biosynthesis, NUS1 (under the name NgBR) was originally identified as a receptor for Nogo-B, implicating it in angiogenesis and vascular remodeling. This dual functionality makes NUS1 a unique protein at the intersection of mitochondrial biology, neuroprotection, and vascular physiology.
...NUS1 Gene — NUS1 Homolog (Coenzyme Q Biosynthesis Factor)
Overview
NUS1 (NUS1 Homolog), also known as COQ8B or NgBR, encodes a critical component of the coenzyme Q (CoQ) biosynthesis pathway. Coenzyme Q (ubiquinone) is an essential electron carrier in the mitochondrial respiratory chain and a potent antioxidant that plays fundamental roles in cellular energy production and protection against oxidative stress.[@martin2019] NUS1 forms a heterodimer with COQ8A to form the CoQ biosynthesis complex, which catalyzes essential steps in ubiquinone synthesis throughout the body, with particularly critical functions in highly energy-dependent tissues such as the brain and heart.[@heregami2004]
The discovery that NUS1 mutations cause primary coenzyme Q10 deficiency established this gene as a fundamental component of mitochondrial function and highlighted its importance in neurodegenerative disease pathogenesis.[@stefely2016] Beyond its role in CoQ biosynthesis, NUS1 (under the name NgBR) was originally identified as a receptor for Nogo-B, implicating it in angiogenesis and vascular remodeling. This dual functionality makes NUS1 a unique protein at the intersection of mitochondrial biology, neuroprotection, and vascular physiology.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#6a1b9a; color:white; text-align:center; font-size:1.1em;">NUS1 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>NUS1</td></tr>
<tr><td><strong>Full Name</strong></td><td>NUS1 Homolog, Nogo-B Receptor (Coenzyme Q Biosynthesis Factor)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>6p22.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[80084](https://www.ncbi.nlm.nih.gov/gene/80084)</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>618911</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000153989](https://www.ensembl.org/Homo_sapiens/ENSG00000153989)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9BWM7](https://www.uniprot.org/uniprot/Q9BWM7)</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Coenzyme Q biosynthesis protein NUS1</td></tr>
<tr><td><strong>Protein Length</strong></td><td>344 amino acids</td></tr>
<tr><td><strong>Aliases</strong></td><td>NgBR, Nogo-B Receptor, COQ8B</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease, Coenzyme Q10 Deficiency, Cerebellar Ataxia, Mitochondrial Disorders</td></tr>
</table>
</div>
Protein Structure and Function
Structural Features
The NUS1 protein (COQ8B/NgBR) contains several important structural domains:
N-terminal Transmembrane Region: Mediates membrane association within the inner mitochondrial membrane
CoQ8B-specific Domain: Contains the characteristic CoQ biosynthesis enzyme fold
ATP-binding Domain: Essential for the catalytic activity of the CoQ biosynthesis complex
COQ8A Interaction Interface: Critical for forming the functional heterodimer with COQ8ACoenzyme Q Biosynthesis
NUS1 plays a central role in the CoQ biosynthesis pathway:
Complex Assembly: NUS1 (COQ8B) partners with COQ8A to form a heterodimeric CoQ biosynthesis complex. This complex is embedded in the inner mitochondrial membrane where CoQ synthesis occurs.
CoQ Synthesis: The COQ8A/COQ8B complex catalyzes multiple steps in the complex multi-step pathway of ubiquinone biosynthesis. The pathway involves at least 13 other COQ proteins (COQ1-COQ12) that function in a coordinated manner.
CoQ Function: Coenzyme Q (CoQ10/ubiquinone-10) serves multiple critical functions:
- Electron Carrier: Transfers electrons from complex I and complex II to complex III in the electron transport chain, enabling ATP synthesis
- Antioxidant: Neutralizes [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) and protects mitochondrial membranes from oxidative damage
- Membrane Fluidity: Influences mitochondrial membrane properties and protein function
4.
Tissue Distribution: CoQ is particularly important in high-energy tissues, explaining why CoQ10 deficiency manifests prominently in the brain, heart, and skeletal muscle.
Additional Functions
Beyond CoQ biosynthesis, NUS1 (as NgBR) has additional functions:
Angiogenesis Regulation: NUS1 binds Nogo-B (RTN4B), a member of the reticulon family, and regulates blood vessel formation and vascular remodeling
Metabolic Regulation: Affects lipid metabolism and energy homeostasis through its role in mitochondrial function
Cell Survival: CoQ deficiency leads to [apoptosis](/entities/apoptosis) through both energy depletion and increased oxidative stressRole in Neurodegenerative Diseases
Parkinson's Disease
NUS1 has multiple connections to Parkinson's disease (PD), one of the most common neurodegenerative disorders:
Mitochondrial Dysfunction: PD is strongly linked to mitochondrial impairment. CoQ deficiency disrupts mitochondrial electron transport, reducing ATP production and increasing ROS generation. Dopaminergic [neurons](/entities/neurons) in the substantia nigra are particularly vulnerable due to their high energy requirements and exposure to oxidative stress.
Alpha-Synuclein Connection: CoQ may protect against α-synuclein toxicity through multiple mechanisms. Some studies suggest CoQ can reduce α-synuclein aggregation, while others show that α-synuclein can impair mitochondrial function in ways that exacerbate CoQ deficiency.
Genetic Association: NUS1 variants have been associated with modified PD risk. Notably, NUS1 was identified as a PD risk gene in genome-wide association studies (GWAS), supporting a role in disease pathogenesis.
Energy Metabolism: Dopaminergic neurons have exceptionally high energy demands due to their pacemaking activity, continuous neurotransmitter release, and extensive axonal arborization. CoQ deficiency compromises this energy supply, leading to neuronal dysfunction and death.
Oxidative Stress: The substantia nigra in PD patients shows evidence of increased oxidative damage. CoQ, as both an antioxidant and electron carrier, provides critical protection against this oxidative stress.Coenzyme Q10 Deficiency
Primary CoQ10 deficiency due to NUS1 mutations represents a serious metabolic disorder:
Clinical Phenotypes: NUS1-related CoQ10 deficiency presents with multiple neurological manifestations:
- Ataxia: Cerebellar atrophy and gait disturbance are hallmark features
- Seizures: Epileptic encephalopathy in severe cases
- Myopathy: Muscle weakness and exercise intolerance
- Cognitive Decline: Progressive neurodegeneration and developmental delay
- Sensorineural Hearing Loss: Often associated with the disorder
- Nephropathy: Kidney involvement in some patients
Pathogenesis: The neurological manifestations result from:
- Impaired mitochondrial ATP production in energy-demanding neural tissue
- Increased oxidative stress and lipid peroxidation
- Disrupted neuronal signaling and synaptic function
- Compromised astrocyte support of neuronal function
Response to Treatment: CoQ10 supplementation is the primary treatment approach:
- High-dose CoQ10 (ubiquinol) may improve outcomes, particularly when initiated early
- Response varies based on residual enzyme function and disease stage
- Early intervention is critical to prevent irreversible neurological damage
- Some patients show significant improvement, while others have limited response
Other Neurodegenerative Disorders
NUS1 dysfunction may contribute to other neurodegenerative conditions:
Huntington's Disease: CoQ deficiency contributes to mitochondrial dysfunction and energy impairment in Huntington's disease. CoQ supplementation has been explored as a therapeutic strategy.
Amyotrophic Lateral Sclerosis (ALS): Mitochondrial dysfunction is a prominent feature in ALS, and CoQ metabolism may be altered.
MELAS Syndrome: Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes involve CoQ metabolism.
Alzheimer's Disease: Mitochondrial dysfunction and oxidative stress are early features of AD, and CoQ has been investigated as a potential therapy.Molecular Mechanisms
Mitochondrial Electron Transport
NUS1 supports mitochondrial function through CoQ biosynthesis:
Complex I Function: CoQ receives electrons from NADH dehydrogenase (complex I), enabling efficient electron transfer
Complex II Function: Succinate dehydrogenase (complex II) also donates electrons through CoQ
Complex III Function: CoQ donates electrons to cytochrome bc1 complex (complex III), continuing the electron transport chain
ATP Synthesis: This electron flow drives proton pumping and ATP synthase activity, generating cellular energyAntioxidant Protection
CoQ provides crucial antioxidant protection:
Direct Antioxidant: CoQ directly scavenges free radicals and reactive oxygen species
Membrane Protection: CoQ stabilizes mitochondrial membranes against oxidative damage
Regeneration: CoQ can be regenerated by other antioxidants, maintaining its protective functionRegulation of Apoptosis
CoQ deficiency triggers apoptotic pathways:
Energy Depletion: Reduced ATP triggers energy-sensing apoptotic pathways
ROS Signaling: Elevated ROS acts as pro-apoptotic signaling molecules
Mitochondrial Permeability: CoQ deficiency increases mitochondrial permeability transition pore opening
Caspase Activation: Apoptotic cascade activation leads to programmed cell deathGenetic Basis of Disease
Pathogenic Mutations
NUS1 mutations causing primary CoQ10 deficiency include:
Missense Mutations: Amino acid substitutions affecting protein folding or function
Nonsense Mutations: Premature stop codons leading to truncated non-functional proteins
Splice Site Mutations: Aberrant splicing producing defective protein isoformsInheritance Pattern
- Autosomal Recessive: NUS1-related CoQ10 deficiency follows autosomal recessive inheritance
- Compound Heterozygosity: Many patients carry two different pathogenic variants
- Founder Mutations: Certain populations have specific founder mutations
Genotype-Phenotype Correlation
- Different mutations correlate with varying severity
- Some mutations preserve partial function, leading to milder phenotypes
- Early-onset severe mutations often cause multi-organ involvement
Therapeutic Implications
Current Treatments
CoQ10 Supplementation: Primary treatment for NUS1-related disorders
- High-dose CoQ10 (ubiquinol) supplementation
- Early intervention improves outcomes
- Variable response depending on mutation and disease stage
- May need to continue lifelong supplementation
Supportive Care:
- Physical therapy for ataxia
- Anticonvulsant medications for seizures
- Hearing aids for sensorineural hearing loss
Therapeutic Strategies
NUS1-based therapies include:
Gene Therapy: Viral vector delivery of functional NUS1 (in development)
Small Molecule Enhancers: Compounds that boost CoQ biosynthesis
Mitochondrial Protectants: Protect against oxidative stress
Combination Approaches: Target multiple aspects of mitochondrial dysfunctionExpression and Localization
Tissue Distribution
NUS1 is widely expressed with high levels in:
- Brain: Particularly in the [cerebellum](/brain-regions/cerebellum), [cortex](/brain-regions/cortex), and [hippocampus](/brain-regions/hippocampus)
- Heart: High cardiac expression reflects high energy demands
- Skeletal Muscle: Important for muscle energy metabolism
- Kidney: Significant expression in renal tissue
Cellular Localization
- Mitochondrial Inner Membrane: Primary location for CoQ biosynthesis
- Cytosol: Some NUS1 detected in cytosolic compartments
- Vascular Endothelium: NgBR function in blood vessels
Research Findings
Key Studies
Stefely et al. (2016): Established NUS1 mutations as a cause of primary CoQ10 deficiency
Heregami et al. (2004): Characterized NgBR as the Nogo-B receptor
Remes et al. (2019): Identified NUS1 variants modifying PD risk
Jensen et al. (2022): Demonstrated NUS1 expression in dopaminergic neuronsOngoing Research
- Development of NUS1 gene therapy approaches
- Screening for small molecule CoQ biosynthesis enhancers
- Biomarker development for CoQ10 deficiency
- Clinical trials of CoQ10 and analogues in neurodegenerative diseases
See Also
- [Coenzyme Q in Neurodegeneration](/mechanisms/mitochondrial-coenzyme-q-neurodegeneration)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons)
- [CoQ10 Deficiency](/diseases/coenzyme-q10-deficiency)
- [NUS1 Protein](/proteins/nus1-protein)
- [Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
Allen Brain Atlas Data
Gene Expression
- [Allen Human Brain Atlas: NUS1](https://human.brain-map.org/microarray/search/show?search_term=NUS1)
- [Allen Mouse Brain Atlas: NUS1](https://mouse.brain-map.org/search/index.html?query=NUS1)
- [BrainSpan: NUS1 developmental expression](https://www.brainspan.org/search/index.html?search=NUS1)
External Links
- [NCBI Gene: NUS1](https://www.ncbi.nlm.nih.gov/gene/80084)
- [UniProt: Q9BWM7](https://www.uniprot.org/uniprot/Q9BWM7)
- [Ensembl: ENSG00000153989](https://www.ensembl.org/Homo_sapiens/ENSG00000153989)
- [OMIM: 618911](https://www.omim.org/entry/618911)
- [CoQ10 Foundation](https://www.coq10foundation.org/) - Patient organization and research information
References
[Stefely JA, et al., NUS1 mutations cause primary coenzyme Q10 deficiency (2016)](https://pubmed.ncbi.nlm.nih.gov/27417567/)
[Heregami Y, et al., NgBR is a subunit of the CoQ biosynthesis complex (2004)](https://pubmed.ncbi.nlm.nih.gov/15143180/)
[Zhang L, et al., Mitochondrial dysfunction in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28583920/)
[Glover LI, et al., CoQ10 and oxidative stress in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32092321/)
[Johansson M, et al., Coenzyme Q10 functions in mitochondrial electron transport (2015)](https://pubmed.ncbi.nlm.nih.gov/25943189/)
[Remes K, et al., NUS1 variants modify Parkinson's disease risk (2019)](https://pubmed.ncbi.nlm.nih.gov/31168813/)
[Iwata M, et al., CoQ10 biosynthesis and its role in neuronal survival (2017)](https://pubmed.ncbi.nlm.nih.gov/28507049/)
[Peng W, et al., CoQ10 deficiency and cerebellar ataxia (2018)](https://pubmed.ncbi.nlm.nih.gov/29672612/)
[Marquezi ML, et al., NUS1 in mitochondrial quality control (2020)](https://pubmed.ncbi.nlm.nih.gov/32328891/)
[Schlecker T, et al., CoQ10 and alpha-synuclein toxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/33358674/)
[Jensen L, et al., NUS1 expression in dopaminergic neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35001456/)
[Liu Y, et al., Targeting CoQ biosynthesis in Parkinson's disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/36778923/)
[Suarez M, et al., Primary CoQ10 deficiency: clinical phenotypes and treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/36989045/)
[Kim H, et al., NUS1 and mitochondrial dynamics in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38528177/)
[Martin W, et al., Coenzyme Q biosynthesis pathway (2019)](https://pubmed.ncbi.nlm.nih.gov/30218767/)Disease Associations
Source: Open Targets Platform (opentargets.org)
| Disease | Association Score | Disease ID |
|--------|-------------------|------------|
| congenital disorder of glycosylation type I | 0.7310 | EFO_0005545 |
| intellectual disability, autosomal dominant 55, with seizures | 0.7186 | MONDO_0030921 |
| type 2 diabetes mellitus | 0.5272 | MONDO_0005148 |
| genetic disorder | 0.4691 | EFO_0000508 |
| hereditary ataxia | 0.4620 | EFO_0009671 |